Skip to main content
. Author manuscript; available in PMC: 2015 Aug 1.
Published in final edited form as: Cancer. 2014 Apr 17;120(15):2289–2298. doi: 10.1002/cncr.28723

Figure 2.

Figure 2

Approach to the management of EGFR mutant NSCLC with progression on first-line EGFR TKI. Here we propose a step-wise approach that considers progression characteristics and clinical trial availability before initiating second-line chemotherapy. RT: Radiation therapy